Purpose As survival rates of adolescent and young adult (AYA) cancer patients increase, a growing number of AYA cancer survivors need follow-up care. However, there is little research on their preferences for follow-up care. We aimed to (1) describe AYA cancer survivors' preferences for the organization and content of follow-up care, (2) describe their preferences for different models of follow-up, and (3) investigate clinical and sociodemographic characteristics associated with preferences for the different models. Methods AYA cancer survivors (diagnosed with cancer at age 16-25 years; ≥5 years after diagnosis) were identified through the Cancer Registry Zurich and Zug. Survivors completed a questionnaire on follow-up attendance, preferences for organizational aspects of follow-up care (what is important during follow-up, what should be included during appointments, what specialists should be involved, location), models of follow-up (telephone/questionnaire, general practitioner (GP), pediatric oncologist, medical oncologist, multidisciplinary team), and sociodemographic characteristics. Information on tumor and treatment was available through the Cancer Registry Zurich and Zug.
Introduction
Survival rates of adolescent and young adult (AYA) cancer patients have increased in the last few decades, resulting in over 75 % of patients surviving for 5 years or more [1] . As survival rates increase, the population of AYA cancer survivors is growing. However, 30 years after diagnosis, more than 60 % of survivors (aged <21 years at diagnosis) have a chronic health condition and about one third has more than one condition [2] . Survivors older at diagnosis were more likely to have a health condition, more severe or multiple conditions [2] . Similarly, another study found that being an AYA at diagnosis, compared to older age at diagnosis, was a risk factor for developing late effects [3] . Therefore, appropriate follow-up is needed for AYA cancer survivors after completion of treatment to detect and treat late effects [3] [4] [5] .
AYA cancer patients and survivors are a particularly vulnerable group to receive adequate care. They are caught between two worlds: trying to leave behind childhood and the pediatric world, with the adult world still ahead [6] , regarding both their medical and their social environment. Therefore, AYA cancer survivors need special attention and follow-up care should be adapted to their needs and preferences.
Different models of long-term follow-up have been suggested for childhood and AYA cancer survivors [5, 7] , including a gatekeeper model with a key-worker (general practitioner (GP) or specialist nurse) [4, 5, [7] [8] [9] , a model with a multidisciplinary team [5, 7, 10] , or different follow-up according to a survivor's risk for late effects [11, 12] . Little is known about the AYA cancer survivors' preferences for different models of long-term follow-up care [13] . Additionally, only attenders of follow-up were included in studies [13] . However, patient acceptance for the model of follow-up is crucial [8] .
Adapting follow-up to survivors' preferences can ensure that the care delivered is not only based on the presumed needs but on the survivors' real needs [5] . It might also help to increase AYA cancer survivors' attendance to follow-up.
We therefore aimed to (1) describe AYA cancer survivors' preferences for the organization and content of follow-up care, (2) describe their preferences for different models of followup, and (3) investigate clinical and sociodemographic characteristics of survivors associated with preferences for the different models.
Methods
Sample and procedure AYA cancer survivors diagnosed in the Canton of Zurich were identified via the Cancer Registry Zurich and Zug in Switzerland. Eligible survivors were aged 16-25 years at diagnosis, diagnosed between January 1990 and December 2005, and were ≥5 years after diagnosis. To allow a direct comparison with pediatric patients from an associated study [14] , the sample was limited to the following diagnoses: leukemia, germ cell tumor, lymphoma, central nervous system tumor (CNS), neuroblastoma, renal, hepatic and bone tumor, and soft tissue sarcoma. All AYA cancer survivors who met the inclusion criteria were included in the study.
Addresses of eligible survivors were available from the Cancer Registry Zurich and Zug and updated by web search and by contacting the community where the survivor had last resided. First, the questionnaire was pilot tested with 30 randomly selected AYA cancer survivors. No changes were made after the pilot testing. A cover letter, study information, informed consent form, questionnaire, and pre-paid return envelope were sent to each survivor. After 4 weeks, we sent non-responders a reminder letter and the same questionnaire again. The questionnaire included information on attendance and preferences for the organization of follow-up care, quality of life, and psychological distress. Questionnaires were sent between August 2010 and January 2012. The study was approved by the Cantonal Ethics Committee of Zurich, and informed consent was obtained from all individual participants included in the study.
Outcome measures assessed by questionnaire
Preferences for the organization and content of follow-up care
What is important in regard to follow-up: Survivors were asked to rate the importance of ten aspects in regard to follow-up appointments on a 4-point Likert scale (0 = "not important" to 3 = "very important"; Fig. 1 ).
What should be included in follow-up: We asked survivors about the importance of different contents of follow-up separately for medical aspects (four items) and general aspects (eight items). Survivors could rate the importance of the 12 aspects on a 4-point Likert scale (0 = "not important" to 3 = "very important"; Fig. 1) .
What specialists should be involved in follow-up: Survivors were asked about the importance of involving certain specialists in follow-up and rated each specialist on a 4-point Likert scale (0 = "not important" to 3 = "very important"; Fig. 1 ).
Where should follow-up be provided: We asked survivors for their level of agreement (0 = "not at all true" to 3 = "totally true") about the place where they would like to attend followup: They could rate four locations (former treating children's hospital, adult hospital, central specialized late effects clinic, current GP's practice).
Preferences for models of follow-up care
We provided a short description of five different models of follow-up: telephone/questionnaire: The survivor is contacted by a medical specialist via telephone or questionnaire to find out whether an appointment with a doctor is required and, if necessary, makes an appointment for a follow-up visit in hospital. GP: The GP is responsible for regular follow-up appointments. If necessary, she/he refers the survivor to the former treating oncologist or another specialist. Former treating pediatric oncologist: Follow-up appointments are held by the former treating oncologist. Medical oncologist: Follow-up appointments are held at a hospital by a medical oncologist. Multidisciplinary team (MDT) in hospital: Follow-up appointments are located at a hospital. A multidisciplinary team is available for specific needs (e.g., cancer specialists, endocrinologists, psychologists, social worker, and nurses). For each model, survivors could rate whether the model would meet their needs on a 4-point Likert scale (0 = "not at all true" to 3 = "totally true"; 
Explanatory variables

Sociodemographic characteristics assessed by questionnaire
We assessed age, sex, educational achievement (primary education: compulsory schooling only; secondary education: vocational training or high school degree; tertiary education: college or university degree [15] ), employment (employed; not employed; in education), partnership (survivors were asked whether they are in a relationship or married (yes/no)), and migration background. We classified participants as having a migration background if they were not Swiss citizens since birth, or were not born in Switzerland.
Clinical characteristics assessed by questionnaire
Survivors were asked whether they suffer from any serious late effects (yes/no), had had a cancer relapse (yes/no) or a second cancer, leukemia, or tumor (yes/no). Survivors were asked whether they still attended follow-up care and could indicate: (a) "I regularly attend follow-up; Intervals between follow-up appointments can be a few months to years"; (b) "I irregularly attend follow-up; I contact my former treating doctor irregularly, especially when I have questions regarding my former illness"; (c) "Follow-up is completed; I visit my treating doctor only when I have specific complaints that are associated with my former illness"; or (d) "Follow-up is completed; I never contact my former treating doctor". We coded those who attended (a) regular or (b) irregular follow-up as attenders, and those who seldom (c) or never (d) visited the former treating doctor as non-attenders of follow-up.
Clinical information from the Cancer Registry Zurich and Zug
We received information on diagnosis (classified according to the International Classification of Childhood Cancer, third edition (ICCC-3) [16] ), age at diagnosis (16-20 years; 21-25 years), treatment (surgery only, chemotherapy (may have had surgery, but not radiotherapy), radiotherapy (may have had surgery and/or chemotherapy)), and time since diagnosis (5-10 years; 11-15 years; 16+ years). For the regression analysis, we grouped diagnoses into four major groups: "leukemia and lymphoma," "CNS tumors," "germ cell tumors," and "others."
Statistical analysis
All analyses were performed using Stata 13.1 (StataCorp, College Station, TX). Descriptive statistics, chi-square tests, and t tests were used to compare participants and non-participants of the study and to calculate the proportion of survivors attending follow-up. For aim 1, means, standard deviations (SD), and 95 % confidence intervals (CI) were used to describe different preferences for organizational and content-related aspects of follow-up. For all variables, paired t tests were used to compare the means. Additionally, we used t tests to analyze differences between attenders and non-attenders of follow-up regarding their preferences for organizational and content-related aspects. For aim 2, we calculated the mean of the four items for each model. Two items were reverse coded, such that a higher score indicated a higher preference for that model. We used paired t tests to compare the different models. The additional four items from the MDT model were analyzed separately using descriptive statistics only. For aim 3, we used univariable linear regression models to investigate clinical and sociodemographic characteristics of survivors associated with preferences for the different models of follow-up care. We used the mean satisfaction of each model as the outcome variable and the participants' clinical and sociodemographic characteristics as explanatory variables. Separate regression analyses were run for each of the five models of follow-up. A significance level of 0.05 (two-tailed) was used for all analyses. All tests were corrected for multiplicity using the Benjamini-Hochberg correction (corrected overall critical p value 0.0072).
Results
Study population
A total of 469 survivors were eligible to participate in the study, of whom 389 (82.9 %) could be contacted (Fig. 3) . Of those contacted, 160 returned the questionnaire (41.1 %). Participants and non-participants of the study were similar in their sociodemographic and differed little in their clinical characteristics (Table 1) . Among participants, 61.3 % (n = 98) were male. The most frequent diagnoses were lymphomas (37.5 %) and germ cell tumors (28.8 %); 44 (27.5 %) reported at least one late effect (Table 1) . Mean age at study was 33.5 years (SD = 5.87; range 20-46 years), mean age at diagnosis 21.1 years (SD = 2.86; range 16-25 years), and mean time since diagnosis 11.9 years (SD = 4.74; range 4-21 years). Of the 160 responders, 92 (57.5 %) reported that they still attended regular (n = 84; 52.5 %) or irregular (n = 8; 5 %) follow-up. Among non-attenders, 16.9 % (n = 27) visited their former treating doctor when they had complaints and 25.6 % (n = 41) never visited their former treating doctor. What is important in regard to follow-up: Competent staff (mean = 2.79; SD = 0.45) and being taken seriously (mean = 2.74; SD = 0.48) were rated highest by survivors ( Fig. 1 ) and significantly higher than the relationship quality (mean = 2.47; SD = 0.68; p < 0.001).
What should be included in follow-up: Medical aspects (mean = 2.52; SD = 0.49) were rated significantly higher than general aspects (mean = 1.23; SD = 0.58; p < 0.001; Fig. 1 ). Among the medical aspects, survivors rated checking for cancer recurrence highest (mean = 2.91; SD = 0.33), followed by screening for late effects (mean = 2.40; SD = 0.71; p < 0.001). Regarding general aspects, learning about the risk for my children was rated highest (mean = 2.02; SD = 1.07).
What specialists should be involved in follow-up: The medical oncologist (mean = 2.50; SD = 0.75; p < 0.001 compared to GP) and the GP (mean = 1.95; SD = 1.00; <0.001 compared to all others) were the staff rated as most important to be included in follow-up (Fig. 1) .
Where should follow-up be provided: Survivors had a clear preference for follow-up at the adult hospital (mean = 2.50; SD = 0.75) over the GP practice (mean = 1.72; SD = 1.05; p < 0.001) and a central specialized late effects clinic (mean = 1.53; SD = 1.06; p < 0.001 compared to the adult hospital; no significant difference compared to the GP practice). Follow-up at a pediatric hospital was least preferred (mean = 0.66; SD = 1.46; p < 0.001 compared to the other three locations).
There were some differences in follow-up preferences between follow-up attenders and non-attenders ( Table 2) . Attenders of follow-up rated regular appointments significantly higher (mean = 2.21; SD = 0.73) than non-attenders (mean = 1.73; SD = 0.90; p < 0.001). Attenders of follow-up rated the involvement of a radiotherapist significantly lower (mean = 1.11; SD = 1.01) than non-attenders (mean = 1.59; SD = 0.90; p = 0.006). The exchange with other survivors was also rated significantly higher by attenders (mean = 0.92; SD = 0.88) than non-attenders (mean = 0.57; SD = 0.63; p = 0.006).
Aim 2: Preferences for different models of follow-up
Survivors rated the follow-up model medical oncologist (mean = 2.47; SD = 0.60) significantly higher than all other models (follow-up by a MDT (p = 0.002), pediatric oncologist (p < 0.001), GP (p < 0.001), and telephone/questionnaire (p < 0.001); Fig. 2) . The follow-up model MDT was also rated highly (mean = 2.27; SD = 0.70) and significantly higher than the two least preferred models (GP (p < 0.001) and telephone/ questionnaire (p < 0.001)), but not significantly higher than follow-up by the pediatric oncologist (mean = 2.18; SD = 0.85; p = 0.387). Regarding hospital-based follow-up by a MDT, survivors agreed that they could contact the specialists they needed (mean = 2.37; SD = 0.74) or would be referred to the right specialist (mean = 2.32; SD = 0.65). Survivors believed that follow-up by a MDT could be less personal (mean = 1.80; SD = 0.98). They saw less of a problem that they would not know who was responsible for them (mean = 1.32; SD = 0.99). Females (mean = 2.53; SD = 0.51) rated the follow-up model MDT significantly higher than males (mean = 2.11; SD = 0.76; p < 0.001; Table 3 ). Survivors not attending follow-up (mean = 1.24; SD = 0.95) rated the model telephone/questionnaire higher than survivors still attending follow-up (mean = 0.76; SD = 0.82; p = 0.001; Table 3 , Fig. 2) . Attenders of follow-up (mean = 1.36; SD = 0.89) reported lower satisfaction with the GP model than nonattenders (mean = 1.85; SD = 0.87; p = 0.001; Table 3 , Fig. 2 ).
Discussion
This is one of the first studies that investigated preferences for the organization of follow-up in AYA cancer survivors. We found that AYA cancer survivors highly valued medical aspects of follow-up. Although our sample had a mean time since diagnosis of 11.9 years, checking for cancer recurrence still seemed to be the most important content of follow-up, followed by screening for late effects. In accordance with these findings, survivors rated the medical oncologist as the most important specialist to be involved in follow-up and had a preference for a medical oncologist-led follow-up model. Survivors not attending follow-up rated both the telephone/ questionnaire and the GP model higher than attenders of follow-up.
In the UK, a study found that AYA cancer survivors rated clinical reasons higher than supportive reasons and that they preferred a consultant-led follow-up model [13] . Another study with childhood cancer survivors showed the same trend [17] . Similarly, a study among clinicians showed the same prioritization for clinical reasons [8] . Regarding the content of follow-up, check that the cancer has not come back is most important for AYA cancer survivors, followed by screening for late effects. Clinicians rated these aspects similarly [8] , such that currently available follow-up is likely to be focusing on medical aspects. This is also reflected in findings of another British study which showed higher satisfaction with the follow-up consultation among survivors seeking clinical support, compared to survivors seeking psychological support [18] .
We found that it is important for AYA cancer survivors to be treated by competent staff and to be taken seriously. This might be especially important for this group who is still at a young age. However, many of them have considerable knowledge about their disease and treatment and might distrust medical staff with little specialization in oncology.
Although our survey was sent a considerable time after diagnosis, the survivors' biggest concern still was cancer relapse, followed by concerns about occurrence of late effects. These concerns might explain why survivors rated the medical oncologist as the most important specialist to be involved in follow-up. Survivors seem to believe that a medical oncologist would be best suited to detect a new cancer or new late effects.
When asked about the suitability of different locations for follow-up, AYA cancer survivors preferred follow-up at the adult hospital over follow-up at the GP practice and other locations. This is in agreement with a previous study among childhood cancer survivors which found that the majority of survivors wanted to continue follow-up at the current clinic [18] . Only a minority of our participants were treated in a pediatric clinic and might prefer to stay there for follow-up. Geographic closeness might be a particular advantage for follow-up care at the GP practice. However, in Switzerland, travel distances to the next adult hospital are usually short.
There were some differences in preferences for follow-up between attenders and non-attenders of follow-up. Attenders rated regular appointments as more important than non-attenders, which could be a reason why non-attenders do not attend follow-up anymore.
Similar to other studies [13, 17] , the most highly rated model of follow-up was medical oncologist-led follow-up. This was followed by the model multidisciplinary team in hospital (MDT). These findings suggest that follow-up by specialists is important to survivors and that they might have less confidence in follow-up by a GP. Although multidisciplinary care has been advocated in previous research [7, 10, 17] , a MDT follow-up model that follows all survivors for the duration of their lives is economically difficult for most health systems. Therefore, a risk-stratification, where survivors with a higher risk for late effects are followed-up by a medical oncologist or a MDT, and survivors with a lower risk for late effects by the GP or via telephone/questionnaire [4, 7] , may be reasonable.
In our study, attenders of follow-up rated the model pediatric hospital higher than non-attenders and the model GP and telephone/questionnaire significantly lower than non-attenders. This might reflect a preference for the model of follow-up these survivors know and still attend. With more time since diagnosis, survivors rated the model pediatric hospital lower. With increasing age, the pediatric hospital is unlikely to be the preferred and best suited model for follow-up of AYA cancer survivors. Well-organized transition of survivors from pediatric to adult care is thus essential.
A reason why non-attenders of follow-up rated the GP and telephone/questionnaire model higher than attenders might be that non-attenders are healthier or suffer from fewer or less severe late effects than attenders. In our sample, non-attenders were less likely to report late effects than attenders of followup (data not shown). Therefore, they might prefer those For all variables, the intercept is in italic CI confidence interval, CNS central nervous system *Significant at corrected significance level (Benjamini-Hochberg) a p value from univariable regression analysis models. Providing healthier survivors with a follow-up model that is acceptable to them might increase their attendance to follow-up. Women rated the model MDT higher than men. A reason for this could be that they expect that the MDT model will include supportive care to a higher level than the other models of follow-up. Previous research has shown that women expect psychological support at follow-up [18] , have more late effects [2] , and rate supportive care higher than men [17] . This raises the question whether follow-up care should be organized differently for male and female survivors.
Because of financial constraints, it is difficult, and from a clinical point of view also not necessary, to follow all survivors by a medical oncologist or a MDT. Therefore, alternative models have to be considered. GP-led follow-up might be acceptable to survivors who no longer want to attend hospital-based follow-up. Close collaboration with specialists and the use of survivorship passports [19] could guarantee high-quality follow-up for these survivors. Further research should try to determine whether Swiss AYA cancer survivors would accept a risk-stratified follow-up.
A limitation of this study is the self-report of medical information on late effects and relapse. Only basic information on eligible participants' clinical background was available from the Cancer Registry Zurich and Zug, and we had no data on survivors' risk for late effects. Therefore, we could not investigate associations between the risk level and preferences for follow-up model. Investigating these associations could help to understand whether survivors would accept a riskstratified approach to follow-up. In Switzerland, so far, no systematic follow-up has been established, and survivors are either followed-up by their oncologist or discharged to primary care. We described different possibilities how follow-up could be organized in the future. However, personal followup experience might have influenced preferences. Another limitation is that the response rate was low (41.1 %). There are two major reasons for this: First, AYA are a mobile and difficult to contact age group and response rates for AYA surveys are usually lower than for other age groups [20] . Second, non-responders to the first questionnaire only received one reminder to participate in the study. Additionally, many participants could not be contacted (n = 80, 17.1 %), limiting the generalizability of our results. We had limited information on AYA cancer survivors who did not participate. Although they were comparable with the participants, it could still be that they would have reported other preferences for follow-up. A major strength of our study is the populationbased sample of AYA cancer survivors for a large and diverse region in Switzerland (Canton of Zurich). Another strength of our study is the self-reported information on preferences of follow-up. We were able to assess in depth information on various aspects of how survivors themselves want their follow-up organized.
Conclusion
For Swiss AYA cancer survivors, the medical reasons for follow-up are of great importance. We found a preference for a medical oncologist-led follow-up model. Better adapting follow-up care to the preferences and needs of survivors might increase attendance and could improve outcomes in the long term.
